What MOTS-c is
For decades the textbook description was simple: the tiny circular genome inside your mitochondria encodes 13 proteins…
A hormone-like peptide written into the mitochondrial genome
For decades the textbook description was simple: the tiny circular genome inside your mitochondria encodes 13 proteins dedicated to energy production. Humanin, found in 2001, was the first sign that this genome also encodes a signaling peptide, and in 2015 Lee and colleagues described a second one: MOTS-c, a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene that circulates in the blood and tunes whole-body metabolism in mice.
That makes MOTS-c genuinely important science. It also makes it a magnet for hype, because "exercise in a molecule" is an easy thing to sell. This free unit sets the honest picture first: what MOTS-c is, where it sits in the mitochondria-derived peptide family, and why almost everything we know still comes from mice and cells, not human trials.
What you'll learn
- What MOTS-c is: a peptide encoded inside mitochondrial 12S rRNA, and why that rewrote a textbook rule
- The core mechanism, from one-carbon metabolism and AICAR to AMPK and the nucleus
- What the exercise-mimetic, performance, aging, and metabolic evidence actually shows (mostly in mice)
- Where MOTS-c stands on human safety, FDA compounding policy, and the WADA prohibited list
What this course covers
10 units take you from the essentials to an in-depth understanding.
- 01 What MOTS-c is A hormone-like peptide written into the mitochondrial genome free
- 02 The molecule and where it comes from Sixteen residues read out of a ribosomal RNA gene paid
- 03 The core mechanism: AICAR and AMPK How a mitochondrial peptide flips the cell’s energy switch paid
- 04 Into the nucleus: mitonuclear signaling A mitochondrial peptide that goes to the nucleus and changes gene programs paid
- 05 The exercise-mimetic hypothesis Exercise raises it, and giving it copies some of exercise, in mice paid
- 06 Performance, aging, and the body map A peptide tied to physical decline, across many tissues, mostly in animals paid
- 07 The metabolic case: insulin, obesity, liver The strongest indication cluster, and where the human data actually lands paid
- 08 Regulation, anti-doping, and trials Not approved, on the WADA list, and without a completed efficacy trial paid
- 09 Administration, handling, and safety How it is used in research, how it is marketed, and how thin the safety data really is paid
- 10 Final exam & certification Pass the final exam to earn your certificate of completion. Exam
Key terms
The 2015 discovery
MOTS-c was not designed in a lab. It was found hiding in a part of the mitochondrial genome nobody expected to make a signaling peptide. The 2015 Cell Metabolism paper showed that this 16-amino-acid fragment improved glucose handling and insulin sensitivity in mice, and that it could be measured circulating in blood, behaving like a hormone the mitochondria send to the rest of the body.
Notice what the timeline does not yet contain: a completed human efficacy trial. The story is a decade of elegant mechanism in mice and cells, plus a growing set of human association studies. That mismatch, deep preclinical science and thin human proof, is the throughline of this entire course.
AdvancedWhy was it hidden for so long?
MOTS-c is read from a small open reading frame nested inside the 12S rRNA gene, a stretch everyone assumed only made ribosomal RNA. Classical mitochondrial genetics counted 13 protein genes and stopped there, so a peptide encoded inside an rRNA region simply was not something researchers were looking for until the humanin precedent told them to look.
The mitochondria-derived peptide family
MOTS-c is not a lone curiosity. It belongs to a small family of mitochondria-derived peptides (MDPs), each encoded by a short reading frame inside mtDNA and each acting like a stress-responsive signal. Seeing the family makes the concept click: the mitochondrion is not just a power plant, it is a signaling organelle that broadcasts its state to the rest of the cell and body.
The family matters because it reframes a textbook organelle. If mtDNA can encode peptide signals at all, then mitochondrial state can be communicated to the nucleus and to distant tissues directly. MOTS-c is simply the family member with the clearest metabolic story, which is why it draws the most attention.
AdvancedMitokine, hormone, or both?
The endocrine label is the literature’s own: the founding paper proposes MOTS-c as a novel key endocrine signal originating from mitochondria, and the later exercise paper reports that it has been dubbed a mitochondrial-encoded hormone or mitokine. What the label does not come with is an identified receptor or any human dose-response: FDA reviewers wrote in 2026 that the molecular targets of MOTS-c remain unknown, and the agency identified no human exposure data at all. So read it as a circulating signal with systemic effects in mice. It also acts inside the cell of origin, so calling it strictly a hormone oversimplifies. The honest phrasing is a stress-responsive mitochondrial signal that can be measured in blood.
Why it rewrote a textbook rule
The reason scientists care is bigger than one peptide. Human mitochondrial DNA is a circle of 16,569 base pairs holding 37 genes: 13 proteins, 22 tRNAs and 2 rRNAs, and the founding MOTS-c paper notes it was traditionally described as encoding just those 13 proteins for energy production. Humanin had already shown that the same genome can encode a signaling peptide, and the 2015 paper presented MOTS-c as a second one that regulates whole-body physiology. Together they changed what the mitochondrion is understood to do.
Keep the significance and the hype separate. Rewriting a textbook rule about mitochondrial biology is a real scientific advance. It does not, by itself, prove that injecting MOTS-c benefits a healthy human, which is a completely different and much harder claim that later units weigh carefully.
The "exercise mimetic" claim, checked
The phrase you will meet most often is exercise in a molecule. It comes from real data: exercise raised MOTS-c in people and in treadmill-trained mice, and given to old mice, MOTS-c improved their physical performance. But "mimetic" is a hypothesis-level word. Holding the popular claims against the actual evidence is the core skill this course builds, so we start practicing now.
None of these claims is flatly absurd. Each is a real preclinical finding rounded up into a human promise. By the final exam you should be able to take any MOTS-c marketing sentence and place it on this same tier map yourself.
AdvancedA better phrase than "exercise mimetic"
A better phrase is exercise-responsive mitochondrial peptide with mimetic features in preclinical models. It is longer, but it keeps three honest facts intact at once: exercise raises it, it copies some adaptations in animals, and the human replacement claim is not established.
The honest evidence ceiling
Before the deeper science, here is the honest map of what is well supported versus merely hopeful. The whole point of this course is to keep these tiers apart instead of rounding everything up to "proven", because MOTS-c is exactly the kind of strong preclinical story that is easy to oversell.
The gap between the green tiers and the red ones is the entire subject of this course. The mechanism work is genuinely substantial, and that is exactly why honest framing matters most here.
This course is education, not medical advice. MOTS-c is investigational, not FDA-approved, and prohibited in sport under WADA. Preclinical findings do not guarantee human benefit.
Reading the evidence like a scientist
A peptide this interesting attracts confident claims, so you need a way to rank what you read. The same hierarchy researchers use for any therapy applies here: a replicated human trial outranks a single mouse study, and an association never proves a treatment works. MOTS-c currently lives in the lower-middle of this pyramid.
When a product page calls MOTS-c "clinically proven", ask which tier the proof lives on. Almost always the honest answer is the bottom two: animal and cell work, with a layer of human association on top, and nothing yet reported at the controlled-trial summit. A phase 2a trial of MOTS-c itself began in 2026 and is recruiting, which is a real step, but a recruiting trial is a question being asked, not an answer. Watch the wording too: the only completed trial in this course’s sources in which anyone received a MOTS-c-like molecule tested the analog CB4211 (NCT03998514, 88 subjects, subcutaneous, completed in 2021), not MOTS-c, and it posted no results either. Completed studies that only measure MOTS-c also exist, such as an exercise trial in breast-cancer survivors (NCT04013568), which is a different thing entirely.
AdvancedAssociation versus causation, concretely
Some human cohorts report lower circulating MOTS-c in disease, and one reports it higher in obesity. The direction is genuinely unsettled: the studies used different assays and different populations, and nothing published reconciles them. That is exactly why a biomarker association cannot tell you whether giving the peptide as a drug helps.